SCHEMBL5043741

SCHEMBL5043741

C=CCNC(=O)c1cc(-c2csc(-c3cnccn3)n2)n(Cc2ccc(OC)cc2)c1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 8/20 0.50
KLK1 P06870 4/20 0.50
RAB9A P51151 2/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
KDM4E B2RXH2 2/20 0.39
HPGD P15428 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
PPARG P37231 1/20 0.39
NCOA2 Q15596 1/20 0.39
NCOA1 Q15788 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39
CYP3A4 P08684 2/20 0.38
MAPT P10636 2/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38
CYP2C19 P33261 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MAPK8 P45983 1/20 0.38
MAPK9 P45984 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5045670 0.89 KLKB1 (0.51) KLKB1KLK1RAB9AMEN1KMT2A
SCHEMBL5043301 0.89 KLKB1 (0.53) KLKB1KLK1RAB9AMEN1KMT2A
SCHEMBL5046948 0.88 KLKB1 (0.50) KLKB1KLK1RAB9AMEN1KMT2A
SCHEMBL5046987 0.87 KLKB1 (0.48) KLKB1KLK1RAB9AMEN1KMT2A
SCHEMBL5044577 0.86 KLKB1 (0.46) KLKB1KLK1RAB9AMEN1KMT2A
SCHEMBL5047122 0.85 KLKB1 (0.46) KLKB1KLK1MEN1KMT2AKDM4E
SCHEMBL5048631 0.85 KLKB1 (0.47) KLKB1KLK1RAB9AMEN1KMT2A
SCHEMBL5043757 0.85 KLKB1 (0.47) KLKB1KLK1RAB9AMEN1KMT2A
SCHEMBL5048709 0.85 HPGD (0.45) KLKB1KLK1RAB9AMEN1KMT2A
SCHEMBL5039546 0.83 KLKB1 (0.43) KLKB1KLK1RAB9AKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583762-B1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS HOFFMANN LA ROCHE (CH) 2008-07-09 EP disclosed
US-7135488-B2 Pyrrolyl-thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
EP-1583762-A1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-12 EP disclosed
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives HOFFMAN-LA ROCHE INC. 2004-07-29 US disclosed
WO-2004060888-A1 NOVEL CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives CNR1, CNR2, NPY1R KLKB1 3949/4885KLK1 3547/4885RAB9A 1009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.